Jeil has completed development of synthetic processes for a wide range of carbapenem active pharmaceutical ingredients (APIs) such as imipenem, panipenem, and meropenem. They are currently being exported to Japan.
Jeil has developed synthetic processes for oral cephalosporin antibiotics such as cefteram, cefditoren, and cefcapene. They are currently being exported to Japan. A synthetic process for cefpodoxime has been established and registered at EDQM (European Directorate for the Quality of Medicines & Healthcare) for export in this area.
Jeil is developing synthetic processes for APIs such as sitagliptin phosphate monohydrate/ phosphate anhydrate/camsilate, linagliptin, and dapagliflozin, an SGLT-2 inhibitor.
Jeil has filed patents for new synthetic processes for adefovir, lamivudine, and entecavir. Drug product of entecavir is going to be exported to Japan.
A synthetic process for irinotecan has been developed and the raw material is on sale for domestic use. Jeil is developing synthetic processes for azacitidine API, which is going to be exported to Japan..
Jeil has developed new synthetic processes for incrementally modified drugs including GI tract medicines, anticoagulants, anti-diabetics, antidepressants, and targeted anti-cancer agents.